Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free MDXG Stock Alerts

MiMedx Group (MDXG) Financials

MiMedx Group logo
$4.20 +0.07 (+1.69%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$4.18 -0.02 (-0.48%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for MiMedx Group

Annual Income Statements for MiMedx Group

This table shows MiMedx Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 29 0.39 65 -30 -26 -83 -29 -30 114 84 49
Consolidated Net Income / (Loss)		 29 0.39 65 -30 -26 -49 -10 -30 58 42 49
Net Income / (Loss) Continuing Operations		 29 0.39 65 -30 -26 -49 -12 -20 67 42 49
Total Pre-Tax Income 		24 0.55 45 -3.40 -26 -62 -12 -20 31 57 66
Total Operating Income		 24 0.88 46 -3.92 -21 -45 -7.05 -15 37 59 64
Total Gross Profit		 167 191 286 323 256 209 202 220 267 289 346
Total Revenue		 187 222 321 359 299 248 242 268 321 349 419
Operating Revenue		 187 222 321 359 299 248 242 268 321 349 419
Total Cost of Revenue		 20 31 35 36 43 39 40 48 55 60 73
Operating Cost of Revenue		 20 31 35 36 43 39 40 48 55 60 73
Total Operating Expenses		 143 190 240 327 277 254 209 234 230 230 282
Selling, General & Admin Expense		 133 173 220 259 198 181 195 209 211 225 266
Research & Development Expense		 8.41 14 18 16 11 12 9.93 13 13 12 15
Amortization Expense		 0.93 2.14 1.68 1.03 1.04 1.07 0.82 0.70 0.76 0.77 0.44
Other Operating Expenses / (Income)		 - 0.00 0.00 51 67 59 3.79 12 5.18 -8.70 0.00
Impairment Charge		 - - 0.00 0.00 0.45 1.03 0.05 0.00 0.00 0.45 0.00
Total Other Income / (Expense), net		 -0.09 -0.34 -1.14 0.53 -4.43 -16 -5.00 -5.02 -6.48 -1.57 2.38
Interest & Investment Income		 - - - - - - - -5.02 -6.46 -1.01 2.93
Other Income / (Expense), net		 - -0.34 -1.05 0.00 0.28 -0.00 -0.02 -0.00 -0.03 -0.57 -0.56
Income Tax Expense		 -5.17 0.16 -20 27 -0.01 -12 0.25 0.21 -37 15 18
Net Income / (Loss) Discontinued Operations		 - - - - - - 2.02 -10 -9.21 0.42 0.00
Basic Earnings per Share		 $0.28 $0.00 $0.61 ($0.28) ($0.24) ($0.77) ($0.15) ($0.33) $0.40 $0.29 $0.33
Weighted Average Basic Shares Outstanding		 105.93M 105.93M 106.12M 105.60M 106.95M 108.26M 110.35M 112.91M 116.50M 146.98M 147.79M
Diluted Earnings per Share		 $0.26 $0.00 $0.56 ($0.28) ($0.24) ($0.77) ($0.15) ($0.33) $0.37 $0.28 $0.32
Weighted Average Diluted Shares Outstanding		 113.63M 112.65M 116.11M 105.60M 106.95M 108.26M 110.35M 112.91M 145.96M 149.05M 149.72M
Weighted Average Basic & Diluted Shares Outstanding		 107.81M 108.84M 106.10M 107.10M 106.60M 111.26M 112.36M 114.08M 146.96M 147.37M 148.57M

Quarterly Income Statements for MiMedx Group

This table shows MiMedx Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 16 43 9.26 18 8.10 -9.50 7.02 9.62 17 15 -11
Consolidated Net Income / (Loss)		 8.53 53 9.26 18 8.10 7.44 7.02 9.62 17 15 -11
Net Income / (Loss) Continuing Operations		 8.84 51 9.06 18 7.88 7.44 7.02 9.62 17 15 -11
Total Pre-Tax Income 		9.43 14 11 23 11 11 8.61 13 23 22 -15
Total Operating Income		 11 15 13 23 11 11 8.25 12 22 21 -16
Total Gross Profit		 67 73 72 72 69 76 72 80 95 99 42
Total Revenue		 82 87 85 87 84 93 88 99 114 118 59
Operating Revenue		 82 87 85 87 84 93 88 99 114 118 59
Total Cost of Revenue		 15 14 13 15 15 17 17 19 19 19 17
Operating Cost of Revenue		 15 14 13 15 15 17 17 19 19 19 17
Total Operating Expenses		 56 57 59 49 58 65 63 68 73 78 58
Selling, General & Admin Expense		 53 54 55 55 54 61 60 64 69 73 53
Research & Development Expense		 3.08 2.43 2.84 3.01 2.92 3.57 3.33 3.30 3.70 4.76 4.14
Amortization Expense		 0.19 0.19 0.19 0.19 0.19 0.19 0.10 0.10 0.11 0.13 0.30
Total Other Income / (Expense), net		 -1.69 -1.58 -1.79 -0.23 0.26 0.20 0.36 0.64 0.66 0.72 0.72
Interest & Investment Income		 -1.68 - -1.69 0.00 0.28 - 0.51 0.74 0.79 0.90 0.89
Other Income / (Expense), net		 -0.01 0.02 -0.10 -0.24 -0.02 -0.21 -0.15 -0.10 -0.13 -0.19 -0.17
Income Tax Expense		 0.59 -37 2.35 5.60 3.54 3.81 1.59 3.39 6.10 6.61 -4.47
Basic Earnings per Share		 $0.06 $0.40 $0.06 $0.12 $0.05 $0.06 $0.05 $0.07 $0.11 $0.10 ($0.07)
Weighted Average Basic Shares Outstanding		 116.30M 116.50M 146.40M 147.33M 146.96M 146.98M 147.27M 147.76M 148.04M 147.79M 148.45M
Diluted Earnings per Share		 $0.06 $0.36 $0.06 $0.12 $0.05 $0.05 $0.05 $0.06 $0.11 $0.10 ($0.07)
Weighted Average Diluted Shares Outstanding		 149.77M 145.96M 150.03M 148.90M 148.37M 149.05M 149.68M 149.32M 149.71M 149.72M 148.45M
Weighted Average Basic & Diluted Shares Outstanding		 116.38M 146.96M 147.60M 146.81M 146.95M 147.37M 147.70M 147.96M 148.10M 148.57M 148.95M

Annual Cash Flow Statements for MiMedx Group

This table details how cash moves in and out of MiMedx Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -18 4.02 -2.85 18 24 27 -8.73 -21 16 22 62
Net Cash From Operating Activities		 19 24 63 36 -39 -30 -1.98 -18 27 66 74
Net Cash From Continuing Operating Activities		 19 24 63 36 -39 -30 -9.87 -7.97 35 67 74
Net Income / (Loss) Continuing Operations		 29 0.39 65 -30 -26 -49 -12 -20 67 42 49
Depreciation Expense		 1.80 3.33 4.09 5.88 6.55 5.78 4.36 3.35 3.43 6.04 15
Non-Cash Adjustments To Reconcile Net Income		 17 19 23 15 -2.80 26 16 15 20 11 24
Changes in Operating Assets and Liabilities, net		 -30 -1.38 -31 44 -20 -16 -19 -7.47 -56 8.15 -14
Net Cash From Discontinued Operating Activities		 - - - - - - 7.89 -9.92 -8.16 -0.93 0.00
Net Cash From Investing Activities		 -0.68 -12 -5.40 -9.22 0.50 -4.56 -3.40 -2.66 -2.16 -9.58 -6.89
Net Cash From Continuing Investing Activities		 -0.68 -12 -5.40 -9.22 0.50 -4.56 -3.40 -2.66 -2.16 -9.58 -6.89
Purchase of Property, Plant & Equipment		 -5.83 -6.21 -5.13 -9.42 -1.75 -4.23 -3.22 -1.51 -1.99 -1.68 -1.03
Acquisitions		 0.00 -7.63 - -0.61 -0.47 -0.33 0.00 0.00 0.00 -7.86 -3.76
Other Investing Activities, net		 -0.85 -0.84 -0.27 - - - -0.25 -1.15 -0.17 -0.04 -2.09
Net Cash From Financing Activities		 -36 -8.15 -60 -8.93 63 62 -3.35 -0.58 -8.57 -34 -5.41
Net Cash From Continuing Financing Activities		 -36 -8.15 -60 -8.93 63 62 -3.35 -0.58 -8.57 -34 -5.41
Repayment of Debt		 -0.50 - -0.03 -0.00 -8.53 -89 - -0.04 -0.05 -82 -1.00
Repurchase of Common Equity		 -40 -10 -68 -7.57 0.00 -7.47 0.00 0.00 -9.52 0.00 0.00
Issuance of Debt		 - - 0.00 0.00 73 60 - 0.00 0.00 50 0.00
Other Financing Activities, net		 4.56 2.23 7.91 -1.36 -1.37 -1.92 -3.35 -0.54 1.00 -2.32 -4.41

Quarterly Cash Flow Statements for MiMedx Group

This table details how cash moves in and out of MiMedx Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 13 0.84 -34 21 20 16 2.02 12 23 24 -6.35
Net Cash From Operating Activities		 13 10 5.98 22 20 19 5.30 14 29 25 1.88
Net Cash From Continuing Operating Activities		 13 9.27 6.79 22 20 19 5.30 14 29 25 1.88
Net Income / (Loss) Continuing Operations		 8.84 51 9.06 18 7.88 7.44 7.02 9.62 17 15 -11
Consolidated Net Income / (Loss)		 - - - - - - 7.02 - - - -11
Depreciation Expense		 0.65 0.61 0.75 0.58 0.58 0.56 3.20 3.17 5.29 3.22 1.62
Non-Cash Adjustments To Reconcile Net Income		 5.14 5.41 6.46 -4.87 4.21 5.13 5.31 5.39 7.29 6.15 0.10
Changes in Operating Assets and Liabilities, net		 -2.10 -48 -9.56 8.11 6.16 3.44 -10 -3.62 -0.00 0.39 11
Net Cash From Investing Activities		 -0.65 -0.48 -6.02 -0.91 0.11 -2.77 -0.41 -0.89 -5.26 -0.34 -5.64
Net Cash From Continuing Investing Activities		 -0.65 -0.48 -6.02 -0.91 0.11 -2.77 -0.41 -0.89 -5.26 -0.34 -5.64
Purchase of Property, Plant & Equipment		 -0.63 -0.43 -1.14 -0.47 -0.17 5.10 -0.38 -0.18 -0.19 -0.29 -0.57
Acquisitions		 - - -5.00 - - - 0.00 -0.74 -3.03 - -5.00
Other Investing Activities, net		 -0.02 -0.05 0.12 -0.43 0.28 -0.01 -0.03 - - -2.05 -0.07
Net Cash From Financing Activities		 0.37 -8.94 -33 -0.36 0.03 -0.40 -2.88 -1.09 -0.86 -0.58 -2.59
Net Cash From Continuing Financing Activities		 0.37 -8.94 -33 -0.36 0.03 -0.40 -2.88 -1.09 -0.86 -0.58 -2.59
Other Financing Activities, net		 0.37 0.63 -1.65 -0.36 0.78 -1.01 -2.88 -1.09 -0.86 0.42 -2.59

Annual Balance Sheets for MiMedx Group

This table presents MiMedx Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 136 117 121 123 167 202 188 171 239 264 343
Total Current Assets		 96 59 49 74 123 161 149 134 164 192 277
Cash & Equivalents		 28 30 27 45 69 96 87 66 82 104 166
Accounts Receivable		 54 - - 0.00 32 35 40 43 54 56 76
Inventories, net		 7.46 16 9.47 16 9.10 10 11 13 21 24 25
Other Current Assets		 0.22 9.52 9.02 5.82 6.06 3.37 2.81 3.34 1.75 7.84 10
Plant, Property, & Equipment, net		 9.48 14 14 17 12 0.00 9.17 7.86 6.97 5.94 4.71
Total Noncurrent Assets		 30 44 58 31 32 41 30 29 68 66 60
Goodwill		 4.04 20 20 20 20 20 20 19 19 19 19
Intangible Assets		 11 23 10 9.61 7.78 6.00 5.38 5.85 5.26 12 14
Noncurrent Deferred & Refundable Income Taxes		 15 0.00 26 - - - - 0.00 41 28 20
Other Noncurrent Operating Assets		 0.49 0.35 2.87 1.79 3.84 15 4.88 3.55 2.34 6.71 7.27
Total Liabilities & Shareholders' Equity		 136 117 121 123 167 202 188 171 239 264 343
Total Liabilities		 28 69 47 73 133 111 95 97 96 71 86
Total Current Liabilities		 27 61 46 72 67 59 42 44 46 46 64
Short-Term Debt		 0.00 - - 0.00 3.75 - - - 1.00 1.00 1.50
Accounts Payable		 6.63 12 8.45 15 8.71 8.77 7.39 8.45 9.05 7.41 15
Accrued Expenses		 4.64 19 16 32 32 30 9.81 11 9.36 9.01 11
Current Employee Benefit Liabilities		 15 13 21 23 21 18 24 21 22 24 31
Other Current Liabilities		 0.53 1.48 0.65 1.82 1.40 1.47 1.57 1.83 2.89 4.51 5.79
Total Noncurrent Liabilities		 1.15 0.88 1.65 1.64 65 51 53 53 50 25 22
Long-Term Debt		 - - - 0.00 62 48 48 49 48 18 16
Other Noncurrent Operating Liabilities		 1.15 0.88 1.65 1.64 3.54 3.76 4.87 4.77 2.22 7.38 5.37
Total Equity & Noncontrolling Interests		 108 48 74 50 34 -0.15 0.08 -18 143 193 257
Total Preferred & Common Equity		 108 48 74 50 34 -0.15 0.08 -18 143 193 257
Total Common Equity		 108 48 74 50 34 -0.15 0.08 -18 143 193 257
Common Stock		 163 162 165 165 147 159 166 174 276 284 299
Retained Earnings		 -38 -111 -47 -77 -102 -151 -162 -192 -134 -91 -43

Quarterly Balance Sheets for MiMedx Group

This table presents MiMedx Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 173 168 176 189 222 230 244 270 291 319 309
Total Current Assets		 136 132 141 155 139 154 172 200 221 254 240
Cash & Equivalents		 73 61 69 81 48 69 89 106 119 142 160
Accounts Receivable		 41 45 49 49 57 53 54 62 69 78 46
Inventories, net		 14 15 17 19 24 25 24 24 25 27 26
Other Current Assets		 2.58 2.31 3.11 2.31 2.80 3.10 2.15 1.97 3.03 3.08 8.29
Plant, Property, & Equipment, net		 7.91 7.56 7.26 7.09 7.34 6.82 6.45 5.77 5.39 5.00 4.76
Total Noncurrent Assets		 29 29 28 27 75 69 65 65 65 60 64
Goodwill		 20 20 19 19 19 19 19 19 19 19 19
Intangible Assets		 4.99 5.71 5.57 5.40 13 12 11 11 12 11 13
Noncurrent Deferred & Refundable Income Taxes		 - - - - 39 33 31 28 27 22 24
Other Noncurrent Operating Assets		 3.88 3.21 2.89 2.59 4.75 4.41 4.02 6.35 5.98 7.66 6.89
Total Liabilities & Shareholders' Equity		 173 168 176 189 222 230 244 270 291 319 309
Total Liabilities		 100 94 97 95 66 62 63 68 74 80 66
Total Current Liabilities		 46 41 44 44 42 40 42 43 50 58 45
Short-Term Debt		 - - - - 1.00 3.20 3.86 1.13 1.25 1.38 1.50
Accounts Payable		 8.82 7.82 8.15 9.17 9.70 7.60 6.92 8.87 8.50 11 11
Accrued Expenses		 11 13 13 9.44 9.20 9.28 8.40 9.45 15 13 11
Current Employee Benefit Liabilities		 24 18 22 23 18 18 20 19 22 28 15
Other Current Liabilities		 1.96 1.79 2.06 1.85 4.07 2.07 2.59 4.44 3.41 4.42 6.05
Total Noncurrent Liabilities		 54 53 52 52 24 22 21 25 24 22 21
Long-Term Debt		 48 49 49 49 18 18 18 18 17 17 16
Other Noncurrent Operating Liabilities		 5.49 4.03 3.25 2.61 5.28 3.88 2.92 7.49 6.98 5.52 5.10
Total Equity & Noncontrolling Interests		 -20 -18 -13 1.33 156 168 181 203 217 239 243
Total Preferred & Common Equity		 -20 -18 -13 1.33 156 168 181 203 217 239 243
Total Common Equity		 -20 -18 -13 1.33 156 168 181 203 217 239 243
Common Stock		 172 179 183 188 280 275 280 287 291 297 296
Retained Earnings		 -191 -197 -196 -187 -124 -107 -99 -84 -75 -58 -54

Annual Metrics And Ratios for MiMedx Group

This table displays calculated financial ratios and metrics derived from MiMedx Group's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 58.43% 18.38% 44.85% 11.82% -16.67% -17.05% -2.50% 10.67% 20.03% 8.52% 19.99%
EBITDA Growth		 194.18% -77.28% 728.80% -94.25% -503.57% -205.79% 97.70% -1,178.11% 479.20% 58.80% 21.56%
EBIT Growth		 243.15% -97.76% 8,188.99% -108.69% -432.03% -117.47% 84.42% -108.24% 351.78% 57.19% 8.63%
NOPAT Growth		 371.87% -97.86% 10,389.68% -104.14% -439.25% -114.55% 84.47% -108.86% 892.63% -47.19% 8.55%
Net Income Growth		 373.41% -98.68% 16,496.67% -146.32% 14.67% -92.67% 79.13% -193.60% 292.83% -27.15% 14.52%
EPS Growth		 420.00% -100.00% 0.00% -150.00% 14.29% -220.83% 80.52% -120.00% 212.12% -24.32% 14.29%
Operating Cash Flow Growth		 11.93% 26.81% 163.91% -43.13% -210.10% 23.21% 93.45% -802.78% 249.64% 147.24% 11.79%
Free Cash Flow Firm Growth		 -699.79% 489.52% 50.60% -33.15% -205.69% -6.87% 65.41% 11.81% 302.99% 66.17% -1.78%
Invested Capital Growth		 106.78% -49.86% 20.76% -90.21% 582.94% 39.75% 23.83% 5.86% 95.85% -2.00% 0.81%
Revenue Q/Q Growth		 7.01% -2.32% 14.62% 1.42% -5.13% -3.07% -6.83% 9.65% 4.03% 1.77% 6.40%
EBITDA Q/Q Growth		 14.14% -72.87% 121.16% -90.22% 27.55% -47.84% 95.21% 46.79% 9.55% -4.21% 21.87%
EBIT Q/Q Growth		 14.57% -96.88% 161.96% -116.27% 16.69% -32.87% 71.04% 40.49% 12.77% -7.40% 18.85%
NOPAT Q/Q Growth		 48.30% -96.88% 259.75% -105.58% 16.13% -32.82% 71.14% 40.50% 153.79% -52.39% 18.66%
Net Income Q/Q Growth		 47.97% -98.04% 172.53% -172.91% 52.92% -22.66% 64.63% -9.54% 1,242.59% -52.05% 18.99%
EPS Q/Q Growth		 44.44% -100.00% 180.00% -177.78% 52.94% -14.93% 54.55% -10.00% 3,800.00% -52.54% 18.52%
Operating Cash Flow Q/Q Growth		 -17.28% 76.61% 10.86% -35.07% -167.09% 29.81% 78.02% -15.43% 145.78% 14.78% 9.10%
Free Cash Flow Firm Q/Q Growth		 -1,115.28% 193.69% 115.67% -74.84% -42.09% 19.18% 20.49% 37.33% 45.23% 18.85% 19.46%
Invested Capital Q/Q Growth		 44.48% -66.52% -56.28% 0.00% 172.35% 3.08% 21.60% 17.69% 80.39% -4.51% -5.81%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 89.21% 86.05% 89.03% 89.87% 85.60% 84.16% 83.63% 81.96% 83.01% 82.78% 82.56%
EBITDA Margin		 14.49% 2.78% 15.91% 0.82% -3.96% -14.61% -0.35% -3.99% 12.60% 18.44% 18.68%
Operating Margin		 13.01% 0.40% 14.39% -1.09% -7.07% -18.29% -2.91% -5.50% 11.55% 16.87% 15.26%
EBIT Margin		 13.01% 0.25% 14.07% -1.09% -6.98% -18.29% -2.92% -5.50% 11.54% 16.71% 15.13%
Profit (Net Income) Margin		 15.72% 0.18% 20.16% -8.35% -8.55% -19.85% -4.25% -11.27% 18.11% 12.16% 11.60%
Tax Burden Percent		 121.29% 71.56% 143.56% 882.51% 99.98% 80.08% 85.32% 152.92% 190.08% 74.04% 73.31%
Interest Burden Percent		 99.65% 100.00% 99.81% 86.57% 122.55% 135.55% 170.40% 134.05% 82.59% 98.27% 104.63%
Effective Tax Rate		 -21.29% 28.44% -43.56% 0.00% 0.00% 0.00% 0.00% 0.00% -120.15% 26.70% 26.69%
Return on Invested Capital (ROIC)		 52.07% 1.10% 156.72% -10.80% -83.40% -85.56% -10.18% -18.68% 97.32% 39.21% 43.38%
ROIC Less NNEP Spread (ROIC-NNEP)		 52.32% 2.28% 165.49% 64.22% -39.02% -17.61% 2.10% 51.47% 192.60% 40.47% 41.89%
Return on Net Nonoperating Assets (RNNOA)		 -22.23% -0.60% -50.49% -37.77% 22.53% 7.21% -0.99% -17.47% -43.70% -13.94% -21.78%
Return on Equity (ROE)		 29.85% 0.50% 106.23% -48.57% -60.87% -78.34% -11.18% -36.15% 53.61% 25.26% 21.61%
Cash Return on Invested Capital (CROIC)		 -17.54% 67.52% 137.92% 153.51% -232.31% -118.72% -31.47% -24.37% 32.52% 41.23% 42.58%
Operating Return on Assets (OROA)		 19.88% 0.43% 37.88% -3.22% -14.40% -24.59% -3.63% -8.20% 18.07% 23.18% 20.88%
Return on Assets (ROA)		 24.02% 0.31% 54.27% -24.56% -17.64% -26.70% -5.27% -16.81% 28.37% 16.87% 16.02%
Return on Common Equity (ROCE)		 29.85% 0.50% 106.23% -48.57% -60.87% -21.33% 0.00% 3.87% 30.78% 25.26% 21.61%
Return on Equity Simple (ROE_SIMPLE)		 27.27% 0.81% 87.71% -60.37% -74.36% 0.00% 0.00% 167.87% 40.80% 21.97% 0.00%
Net Operating Profit after Tax (NOPAT)		 30 0.63 66 -2.75 -15 -32 -4.94 -10 82 43 47
NOPAT Margin		 15.78% 0.29% 20.66% -0.76% -4.95% -12.80% -2.04% -3.85% 25.42% 12.37% 11.19%
Net Nonoperating Expense Percent (NNEP)		 -0.25% -1.18% -8.76% -75.03% -44.38% -67.95% -12.29% -70.15% -95.28% -1.26% 1.49%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -33.68% 42.60% 20.22% 17.06%
Cost of Revenue to Revenue		 10.79% 13.95% 10.97% 10.13% 14.40% 15.84% 16.37% 18.04% 16.99% 17.22% 17.44%
SG&A Expenses to Revenue		 71.22% 78.22% 68.54% 71.99% 66.23% 72.92% 80.51% 77.91% 65.67% 64.52% 63.59%
R&D to Revenue		 4.49% 6.47% 5.57% 4.39% 3.72% 4.72% 4.10% 4.74% 3.94% 3.54% 3.61%
Operating Expenses to Revenue		 76.21% 85.65% 74.64% 90.96% 92.67% 102.44% 86.54% 87.46% 71.46% 65.91% 67.30%
Earnings before Interest and Taxes (EBIT)		 24 0.55 45 -3.92 -21 -45 -7.07 -15 37 58 63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 27 6.17 51 2.94 -12 -36 -0.84 -11 41 64 78
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 9.45 20.19 18.97 5.39 24.47 0.00 8,260.40 0.00 7.15 7.32 3.91
Price to Tangible Book Value (P/TBV)		 10.96 210.66 31.98 13.33 126.66 0.00 0.00 0.00 8.65 8.72 4.50
Price to Revenue (P/Rev)		 5.45 4.38 4.36 0.75 2.81 4.06 2.80 1.18 3.17 4.05 2.40
Price to Earnings (P/E)		 34.67 2,487.95 21.63 0.00 0.00 0.00 0.00 0.00 17.53 33.33 20.64
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 2.88% 0.04% 4.62% 0.00% 0.00% 0.00% 0.00% 0.00% 5.71% 3.00% 4.85%
Enterprise Value to Invested Capital (EV/IC)		 12.93 24.50 29.63 49.04 27.05 24.29 13.63 6.89 8.88 12.20 7.88
Enterprise Value to Revenue (EV/Rev)		 5.28 4.24 4.27 0.62 2.80 4.24 3.02 1.46 3.07 3.81 2.04
Enterprise Value to EBITDA (EV/EBITDA)		 36.46 152.45 26.86 75.70 0.00 0.00 0.00 0.00 24.38 20.66 10.93
Enterprise Value to EBIT (EV/EBIT)		 40.61 1,724.73 30.39 0.00 0.00 0.00 0.00 0.00 26.63 22.80 13.49
Enterprise Value to NOPAT (EV/NOPAT)		 33.49 1,485.93 20.69 0.00 0.00 0.00 0.00 0.00 12.09 30.81 18.24
Enterprise Value to Operating Cash Flow (EV/OCF)		 52.61 39.41 21.81 6.22 0.00 0.00 0.00 0.00 36.89 20.08 11.55
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 24.24 23.51 5.70 0.00 0.00 0.00 0.00 36.17 29.30 18.59
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 1.91 0.52 0.52 0.65 0.34 0.10 0.07
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 1.80 0.52 0.52 0.65 0.34 0.09 0.06
Financial Leverage		 -0.42 -0.26 -0.31 -0.59 -0.58 -0.41 -0.47 -0.34 -0.23 -0.34 -0.52
Leverage Ratio		 1.24 1.62 1.96 1.98 3.45 2.93 2.12 2.15 1.89 1.50 1.35
Compound Leverage Factor		 1.24 1.62 1.95 1.71 4.23 3.98 3.61 2.88 1.56 1.47 1.41
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 65.62% 34.29% 34.20% 39.48% 25.60% 9.49% 6.55%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 3.75% 0.00% 0.00% 0.00% 0.52% 1.13% 0.55%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 61.87% 34.29% 34.20% 39.48% 25.08% 8.36% 6.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 65.82% 65.74% 75.14% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 34.38% -0.11% 0.06% -14.61% 74.40% 90.51% 93.46%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -5.54 -1.32 -57.57 -4.55 1.21 0.31 0.23
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.29 1.33 46.60 1.62 -0.81 -1.31 -1.89
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -5.22 -1.32 -57.57 -4.55 1.19 0.28 0.21
Debt to NOPAT		 0.00 0.00 0.00 0.00 -4.43 -1.50 -9.75 -4.71 0.60 0.47 0.38
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.23 1.51 7.89 1.68 -0.40 -1.95 -3.16
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -4.18 -1.50 -9.75 -4.71 0.59 0.41 0.35
Altman Z-Score		 24.13 8.98 21.07 4.16 4.73 5.51 4.90 2.30 8.02 14.21 9.39
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 72.78% 100.04% 110.72% 42.58% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.60 0.98 1.06 1.04 1.83 2.71 3.51 3.08 3.57 4.21 4.32
Quick Ratio		 3.18 0.50 0.60 0.63 1.51 2.22 3.01 2.50 2.95 3.51 3.76
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -9.95 39 58 39 -41 -44 -15 -13 27 45 46
Operating Cash Flow to CapEx		 322.76% 384.35% 1,227.84% 381.25% -2,249.54% -715.78% -61.59% -1,181.84% 1,347.51% 3,933.33% 7,163.89%
Free Cash Flow to Firm to Interest Expense		 -115.75 0.00 671.20 0.00 -8.76 -2.73 -3.06 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 218.69 0.00 723.44 0.00 -8.37 -1.87 -0.40 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 150.93 0.00 664.52 0.00 -8.74 -2.14 -1.04 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.53 1.75 2.69 2.94 2.06 1.34 1.24 1.49 1.57 1.39 1.38
Accounts Receivable Turnover		 4.66 0.00 0.00 0.00 0.00 7.33 6.39 6.42 6.63 6.36 6.37
Inventory Turnover		 3.21 2.65 2.78 2.86 3.43 4.04 3.64 3.93 3.19 2.68 2.97
Fixed Asset Turnover		 25.10 18.90 22.88 22.79 20.12 0.00 0.00 31.47 43.36 54.01 78.56
Accounts Payable Turnover		 3.93 3.25 3.38 3.12 3.66 4.50 4.91 6.10 6.24 7.30 6.66
Days Sales Outstanding (DSO)		 78.37 0.00 0.00 0.00 0.00 49.81 57.14 56.85 55.04 57.38 57.34
Days Inventory Outstanding (DIO)		 113.76 137.63 131.30 127.66 106.29 90.32 100.17 92.81 114.26 136.19 122.85
Days Payable Outstanding (DPO)		 92.99 112.34 108.12 116.96 99.86 81.09 74.38 59.83 58.46 50.00 54.83
Cash Conversion Cycle (CCC)		 99.14 25.29 23.18 10.71 6.42 59.04 82.93 89.84 110.83 143.57 125.36
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 77 38 46 4.54 31 43 54 57 111 109 108
Invested Capital Turnover		 3.30 3.86 7.58 14.12 16.85 6.68 4.99 4.85 3.83 3.17 3.88
Increase / (Decrease) in Invested Capital		 40 -38 7.96 -42 26 12 10 3.14 54 -2.23 0.87
Enterprise Value (EV)		 989 940 1,373 222 838 1,052 731 391 988 1,329 854
Market Capitalization		 1,021 970 1,400 268 842 1,008 677 316 1,021 1,414 1,003
Book Value per Share		 $0.99 $0.44 $0.66 $0.45 $0.31 $0.00 $0.00 ($0.16) $1.23 $1.31 $1.73
Tangible Book Value per Share		 $0.86 $0.04 $0.39 $0.18 $0.06 ($0.24) ($0.23) ($0.38) $1.01 $1.10 $1.51
Total Capital		 108 48 74 50 100 139 141 123 192 213 275
Total Debt		 0.00 0.00 0.00 0.00 66 48 48 49 49 20 18
Total Long-Term Debt		 0.00 0.00 0.00 0.00 62 48 48 49 48 18 16
Net Debt		 -31 -30 -27 -45 -3.41 -48 -39 -17 -33 -84 -148
Capital Expenditures (CapEx)		 5.83 6.21 5.13 9.39 1.75 4.23 3.22 1.51 1.99 1.68 1.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 38 -32 -25 -43 -9.40 5.64 19 25 37 44 49
Debt-free Net Working Capital (DFNWC)		 70 -1.32 2.94 2.50 60 101 106 91 119 149 215
Net Working Capital (NWC)		 70 -1.32 2.94 2.50 56 101 106 91 118 146 213
Net Nonoperating Expense (NNE)		 0.10 0.24 1.63 27 11 18 5.35 20 23 0.73 -1.74
Net Nonoperating Obligations (NNO)		 -31 -9.71 -27 -45 -3.41 -48 -39 -18 -32 -84 -148
Total Depreciation and Amortization (D&A)		 2.77 5.62 5.93 6.86 9.02 9.13 6.24 4.05 3.43 6.04 15
Debt-free, Cash-free Net Working Capital to Revenue		 20.31% -14.27% -7.64% -11.87% -3.14% 2.27% 7.88% 9.22% 11.59% 12.70% 11.61%
Debt-free Net Working Capital to Revenue		 37.12% -0.59% 0.91% 0.70% 19.94% 40.87% 43.87% 33.84% 37.10% 42.63% 51.29%
Net Working Capital to Revenue		 37.12% -0.59% 0.91% 0.70% 18.69% 40.87% 43.87% 33.84% 36.78% 41.93% 50.93%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.28 $0.11 $0.61 ($0.28) ($0.24) ($0.77) ($0.15) ($0.33) $0.40 $0.29 $0.33
Adjusted Weighted Average Basic Shares Outstanding		 105.93M 105.93M 106.12M 105.60M 106.95M 108.26M 110.35M 112.91M 116.50M 146.98M 147.79M
Adjusted Diluted Earnings per Share		 $0.26 $0.11 $0.56 ($0.28) ($0.24) ($0.77) ($0.15) ($0.33) $0.37 $0.28 $0.32
Adjusted Weighted Average Diluted Shares Outstanding		 113.63M 112.44M 116.11M 105.60M 106.95M 108.26M 110.35M 112.91M 145.96M 149.05M 149.72M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.24) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 107.81M 108.84M 106.10M 107.10M 106.60M 111.26M 112.36M 114.08M 146.96M 147.37M 148.57M
Normalized Net Operating Profit after Tax (NOPAT)		 17 0.63 32 -2.75 -14 -31 -4.90 -10 26 43 47
Normalized NOPAT Margin		 9.11% 0.29% 10.08% -0.76% -4.85% -12.51% -2.02% -3.85% 8.08% 12.46% 11.19%
Pre Tax Income Margin		 12.96% 0.25% 14.04% -0.95% -8.55% -24.79% -4.98% -7.37% 9.53% 16.42% 15.83%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 283.30 0.00 519.25 0.00 -4.43 -2.81 -1.42 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 343.61 0.00 762.72 0.00 -3.15 -1.97 -0.99 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 215.55 0.00 460.33 0.00 -4.81 -3.07 -2.07 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 275.85 0.00 703.80 0.00 -3.52 -2.23 -1.64 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 136.79% 2,661.03% 105.46% -25.26% 0.00% -15.16% 0.00% 0.00% 16.34% 0.00% 0.00%

Quarterly Metrics And Ratios for MiMedx Group

This table displays calculated financial ratios and metrics derived from MiMedx Group's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 148,566,586.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 148,566,586.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.07
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 20.72% 16.75% 18.18% 7.32% 2.87% 7.00% 4.13% 13.07% 35.30% 27.11% -33.12%
EBITDA Growth		 306.21% 33.51% 1,925.47% 110.09% 1.51% -14.56% -17.76% -36.63% 122.46% 74.24% -229.10%
EBIT Growth		 256.46% 37.14% 3,975.44% 114.80% 0.25% -30.06% -38.12% -47.15% 98.04% 92.59% -300.06%
NOPAT Growth		 309.71% 406.29% 4,504.13% 62.90% -26.15% -87.20% -35.81% -48.61% 111.21% 100.96% -266.96%
Net Income Growth		 201.28% 13,017.15% 285.85% 1,368.75% -5.14% -86.09% -24.17% -45.43% 106.89% 104.21% -254.63%
EPS Growth		 166.67% 1,900.00% 200.00% 1,100.00% -16.67% -86.11% -16.67% -50.00% 120.00% 100.00% -240.00%
Operating Cash Flow Growth		 1,233.79% 282.38% 247.68% 180.57% 53.42% 83.11% -11.36% -33.90% 49.45% 32.87% -64.54%
Free Cash Flow Firm Growth		 67.43% -66.78% -1,070.92% -857.46% -1,408.57% 252.72% 134.42% 131.73% 134.12% 26.10% -83.95%
Invested Capital Growth		 27.77% 95.85% 104.77% 101.06% 85.12% -2.00% -9.48% -3.69% 0.87% 0.81% -12.39%
Revenue Q/Q Growth		 0.56% 6.27% -2.45% 2.95% -3.61% 10.53% -5.06% 11.79% 15.33% 3.84% -50.05%
EBITDA Q/Q Growth		 6.62% 29.27% -16.93% 74.58% -48.48% 8.81% -15.96% 34.89% 77.20% -11.86% -160.56%
EBIT Q/Q Growth		 2.83% 39.55% -17.18% 77.21% -52.01% -2.64% -25.27% 51.36% 79.84% -5.32% -177.63%
NOPAT Q/Q Growth		 -4.57% 447.69% -81.71% 69.80% -56.73% -5.09% -7.94% 35.94% 77.82% -9.69% -176.48%
Net Income Q/Q Growth		 611.17% 526.63% -82.68% 90.31% -54.07% -8.12% -5.58% 36.95% 74.13% -9.31% -171.50%
EPS Q/Q Growth		 500.00% 500.00% -83.33% 100.00% -58.33% 0.00% 0.00% 20.00% 83.33% -9.09% -170.00%
Operating Cash Flow Q/Q Growth		 64.51% -19.81% -41.72% 264.90% -10.04% -4.29% -71.79% 172.11% 103.41% -14.91% -92.47%
Free Cash Flow Firm Q/Q Growth		 -152.44% 191.11% -1,967.41% 21.40% -4.45% 121.30% 96.82% -27.55% 12.33% -9.54% -78.20%
Invested Capital Q/Q Growth		 2.69% 80.39% 14.28% -5.02% -5.45% -4.51% 5.56% 1.05% -0.98% -5.81% -7.05%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 81.90% 84.06% 84.67% 82.97% 81.77% 81.80% 81.23% 81.05% 83.54% 83.86% 70.56%
EBITDA Margin		 15.09% 18.36% 16.43% 27.86% 14.89% 14.66% 12.97% 15.66% 24.05% 20.42% -24.75%
Operating Margin		 13.61% 17.84% 15.58% 26.89% 13.28% 11.90% 9.35% 12.55% 19.51% 17.85% -27.21%
EBIT Margin		 13.60% 17.86% 15.46% 26.62% 13.25% 11.68% 9.19% 12.44% 19.40% 17.69% -27.49%
Profit (Net Income) Margin		 10.44% 61.59% 10.93% 20.21% 9.63% 8.01% 7.96% 9.75% 14.73% 12.86% -18.41%
Tax Burden Percent		 90.47% 384.34% 81.17% 75.92% 70.89% 66.12% 81.55% 73.94% 73.30% 69.69% 70.84%
Interest Burden Percent		 84.88% 89.72% 87.10% 100.01% 102.50% 103.72% 106.24% 106.02% 103.56% 104.33% 94.54%
Effective Tax Rate		 6.27% -268.61% 20.58% 24.10% 31.01% 33.88% 18.45% 26.06% 26.70% 30.31% 0.00%
Return on Invested Capital (ROIC)		 71.79% 251.81% 43.78% 76.92% 35.75% 24.94% 22.21% 28.49% 49.11% 48.23% -68.74%
ROIC Less NNEP Spread (ROIC-NNEP)		 78.44% 266.54% 49.71% 77.43% 34.95% 24.72% 21.71% 27.85% 48.60% 47.80% -69.07%
Return on Net Nonoperating Assets (RNNOA)		 -26.78% -60.48% -8.89% -20.99% -12.61% -8.52% -7.05% -10.70% -22.08% -24.85% 35.63%
Return on Equity (ROE)		 45.01% 191.32% 34.89% 55.93% 23.14% 16.42% 15.16% 17.79% 27.03% 23.38% -33.11%
Cash Return on Invested Capital (CROIC)		 34.23% 32.52% 26.91% 37.73% 43.46% 41.23% 42.61% 29.85% 33.58% 42.58% 39.82%
Operating Return on Assets (OROA)		 23.23% 27.97% 26.54% 44.58% 20.99% 16.20% 13.16% 17.37% 27.12% 24.42% -36.97%
Return on Assets (ROA)		 17.84% 96.47% 18.76% 33.85% 15.25% 11.11% 11.40% 13.61% 20.59% 17.75% -24.76%
Return on Common Equity (ROCE)		 -4.91% 109.86% 20.88% 35.06% 15.35% 16.42% 15.16% 17.79% 27.03% 23.38% -33.11%
Return on Equity Simple (ROE_SIMPLE)		 326.09% 0.00% 46.54% 52.90% 48.87% 0.00% 19.82% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 10 57 10 18 7.70 7.31 6.73 9.15 16 15 -11
NOPAT Margin		 12.76% 65.77% 12.37% 20.41% 9.16% 7.87% 7.63% 9.28% 14.30% 12.44% -19.04%
Net Nonoperating Expense Percent (NNEP)		 -6.65% -14.73% -5.93% -0.52% 0.80% 0.22% 0.51% 0.64% 0.51% 0.43% 0.33%
Return On Investment Capital (ROIC_SIMPLE)		 - 29.77% - - - 3.43% 3.04% 3.89% 6.32% 5.35% -4.31%
Cost of Revenue to Revenue		 18.10% 15.94% 15.33% 17.03% 18.23% 18.20% 18.77% 18.95% 16.46% 16.14% 29.44%
SG&A Expenses to Revenue		 64.34% 62.59% 65.08% 63.53% 63.67% 65.70% 67.99% 65.06% 60.67% 61.88% 90.24%
R&D to Revenue		 3.76% 2.80% 3.35% 3.45% 3.47% 3.84% 3.77% 3.35% 3.26% 4.03% 7.02%
Operating Expenses to Revenue		 68.29% 66.22% 69.09% 56.08% 68.49% 69.90% 71.87% 68.51% 64.03% 66.02% 97.76%
Earnings before Interest and Taxes (EBIT)		 11 16 13 23 11 11 8.11 12 22 21 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 12 16 14 24 13 14 11 15 27 24 -15
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 636.42 7.15 5.75 6.09 4.79 7.32 5.52 4.17 4.32 3.91 2.42
Price to Tangible Book Value (P/TBV)		 0.00 8.65 7.24 7.49 5.77 8.72 6.50 4.87 4.96 4.50 2.79
Price to Revenue (P/Rev)		 2.74 3.17 2.68 3.00 2.53 4.05 3.18 2.48 2.62 2.40 1.51
Price to Earnings (P/E)		 0.00 17.53 6.36 6.83 5.78 33.33 27.87 28.05 25.30 20.64 19.12
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 5.71% 15.73% 14.65% 17.31% 3.00% 3.59% 3.57% 3.95% 4.85% 5.23%
Enterprise Value to Invested Capital (EV/IC)		 14.71 8.88 6.83 8.08 7.02 12.20 8.98 6.90 7.90 7.88 4.41
Enterprise Value to Revenue (EV/Rev)		 2.93 3.07 2.59 2.86 2.34 3.81 2.93 2.20 2.31 2.04 1.14
Enterprise Value to EBITDA (EV/EBITDA)		 24.52 24.38 15.98 14.56 11.92 20.66 16.68 16.33 14.16 10.93 8.50
Enterprise Value to EBIT (EV/EBIT)		 27.57 26.63 17.16 15.50 12.72 22.80 19.36 18.93 17.06 13.49 11.40
Enterprise Value to NOPAT (EV/NOPAT)		 28.16 12.09 9.59 10.29 8.83 30.81 26.11 25.95 23.03 18.24 15.49
Enterprise Value to Operating Cash Flow (EV/OCF)		 83.23 36.89 23.56 19.18 13.88 20.08 15.75 13.80 13.40 11.55 6.30
Enterprise Value to Free Cash Flow (EV/FCFF)		 48.22 36.17 34.08 28.61 20.97 29.30 20.01 22.68 23.62 18.59 10.35
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.52 0.34 0.12 0.13 0.12 0.10 0.09 0.09 0.08 0.07 0.07
Long-Term Debt to Equity		 0.52 0.34 0.12 0.11 0.10 0.09 0.09 0.08 0.07 0.06 0.07
Financial Leverage		 -0.34 -0.23 -0.18 -0.27 -0.36 -0.34 -0.32 -0.38 -0.45 -0.52 -0.52
Leverage Ratio		 2.17 1.89 1.69 1.64 1.58 1.50 1.37 1.36 1.34 1.35 1.30
Compound Leverage Factor		 1.84 1.70 1.47 1.64 1.61 1.55 1.46 1.44 1.39 1.41 1.23
Debt to Total Capital		 34.29% 25.60% 11.10% 11.32% 10.78% 9.49% 8.43% 7.85% 7.08% 6.55% 6.75%
Short-Term Debt to Total Capital		 0.00% 0.52% 0.57% 1.69% 1.90% 1.13% 0.51% 0.53% 0.53% 0.55% 0.58%
Long-Term Debt to Total Capital		 34.29% 25.08% 10.53% 9.63% 8.88% 8.36% 7.92% 7.32% 6.55% 6.00% 6.18%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 64.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.93% 74.40% 88.90% 88.68% 89.22% 90.51% 91.57% 92.15% 92.92% 93.46% 93.25%
Debt to EBITDA		 1.32 1.21 0.36 0.32 0.33 0.31 0.30 0.38 0.28 0.23 0.34
Net Debt to EBITDA		 -0.87 -0.81 -0.54 -0.71 -1.00 -1.31 -1.42 -2.04 -1.93 -1.89 -2.72
Long-Term Debt to EBITDA		 1.32 1.19 0.34 0.27 0.27 0.28 0.28 0.35 0.26 0.21 0.31
Debt to NOPAT		 1.52 0.60 0.22 0.23 0.24 0.47 0.47 0.60 0.46 0.38 0.61
Net Debt to NOPAT		 -1.00 -0.40 -0.32 -0.50 -0.74 -1.95 -2.22 -3.25 -3.14 -3.16 -4.95
Long-Term Debt to NOPAT		 1.52 0.59 0.20 0.19 0.20 0.41 0.44 0.56 0.43 0.35 0.56
Altman Z-Score		 6.48 7.73 9.59 11.63 9.91 13.62 11.60 9.00 9.69 8.98 6.96
Noncontrolling Interest Sharing Ratio		 110.91% 42.58% 40.17% 37.32% 33.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.54 3.57 3.29 3.85 4.10 4.21 4.70 4.39 4.41 4.32 5.39
Quick Ratio		 2.98 2.95 2.50 3.05 3.41 3.51 3.96 3.74 3.82 3.76 4.62
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.97 2.70 -55 -43 -45 9.54 19 14 15 14 3.01
Operating Cash Flow to CapEx		 2,036.78% 2,402.11% 97.30% 4,631.42% 11,476.02% 0.00% 1,405.57% 8,055.31% 15,275.52% 8,756.49% 329.65%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -32.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 3.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.71 1.57 1.72 1.67 1.58 1.39 1.43 1.40 1.40 1.38 1.34
Accounts Receivable Turnover		 6.88 6.63 6.58 6.69 6.65 6.36 5.91 5.96 5.95 6.37 7.19
Inventory Turnover		 3.34 3.19 2.82 2.70 2.63 2.68 2.62 2.70 2.79 2.97 2.94
Fixed Asset Turnover		 41.19 43.36 44.89 48.35 50.62 54.01 53.74 59.58 68.70 78.56 73.97
Accounts Payable Turnover		 6.13 6.24 6.30 7.17 7.08 7.30 6.86 8.38 7.73 6.66 7.26
Days Sales Outstanding (DSO)		 53.05 55.04 55.49 54.55 54.85 57.38 61.79 61.22 61.33 57.34 50.77
Days Inventory Outstanding (DIO)		 109.33 114.26 129.30 135.31 138.68 136.19 139.14 135.10 130.70 122.85 124.34
Days Payable Outstanding (DPO)		 59.52 58.46 57.92 50.91 51.52 50.00 53.24 43.55 47.23 54.83 50.26
Cash Conversion Cycle (CCC)		 102.86 110.83 126.87 138.95 142.01 143.57 147.70 152.76 144.80 125.36 124.85
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 62 111 127 121 114 109 115 116 115 108 101
Invested Capital Turnover		 5.63 3.83 3.54 3.77 3.90 3.17 2.91 3.07 3.43 3.88 3.61
Increase / (Decrease) in Invested Capital		 13 54 65 61 52 -2.23 -12 -4.45 0.99 0.87 -14
Enterprise Value (EV)		 907 988 867 975 801 1,329 1,032 802 909 854 445
Market Capitalization		 846 1,021 896 1,023 868 1,414 1,120 902 1,033 1,003 587
Book Value per Share		 $0.01 $1.23 $1.06 $1.14 $1.23 $1.31 $1.38 $1.47 $1.61 $1.73 $1.64
Tangible Book Value per Share		 ($0.20) $1.01 $0.85 $0.93 $1.02 $1.10 $1.17 $1.25 $1.41 $1.51 $1.42
Total Capital		 143 192 175 189 203 213 221 235 257 275 261
Total Debt		 49 49 19 21 22 20 19 18 18 18 18
Total Long-Term Debt		 49 48 18 18 18 18 18 17 17 16 16
Net Debt		 -32 -33 -29 -48 -67 -84 -88 -100 -124 -148 -142
Capital Expenditures (CapEx)		 0.63 0.43 6.14 0.47 0.17 -5.10 0.38 0.18 0.19 0.29 0.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 30 37 49 48 45 44 52 53 56 49 38
Debt-free Net Working Capital (DFNWC)		 111 119 98 117 134 149 159 172 198 215 197
Net Working Capital (NWC)		 111 118 97 114 130 146 157 171 196 213 196
Net Nonoperating Expense (NNE)		 1.89 3.63 1.22 0.17 -0.39 -0.13 -0.29 -0.47 -0.48 -0.50 -0.37
Net Nonoperating Obligations (NNO)		 -32 -32 -29 -47 -67 -84 -88 -100 -124 -148 -142
Total Depreciation and Amortization (D&A)		 1.22 0.43 0.82 1.08 1.37 2.77 3.34 3.17 5.29 3.22 1.62
Debt-free, Cash-free Net Working Capital to Revenue		 9.61% 11.59% 14.69% 14.15% 13.20% 12.70% 14.81% 14.56% 14.16% 11.61% 9.63%
Debt-free Net Working Capital to Revenue		 35.88% 37.10% 29.19% 34.42% 39.11% 42.63% 45.01% 47.24% 50.27% 51.29% 50.66%
Net Working Capital to Revenue		 35.88% 36.78% 28.89% 33.49% 37.98% 41.93% 44.69% 46.89% 49.92% 50.93% 50.27%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.06 $0.40 $0.06 $0.12 $0.05 $0.06 $0.05 $0.07 $0.11 $0.10 ($0.07)
Adjusted Weighted Average Basic Shares Outstanding		 116.30M 116.50M 146.40M 147.33M 146.96M 146.98M 147.27M 147.76M 148.04M 147.79M 148.45M
Adjusted Diluted Earnings per Share		 $0.06 $0.36 $0.06 $0.12 $0.05 $0.05 $0.05 $0.06 $0.11 $0.10 ($0.07)
Adjusted Weighted Average Diluted Shares Outstanding		 119.33M 145.96M 150.03M 148.90M 148.37M 149.05M 149.68M 149.32M 149.71M 149.72M 148.45M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 116.38M 146.96M 147.60M 146.81M 146.95M 147.37M 147.70M 147.96M 148.10M 148.57M 148.95M
Normalized Net Operating Profit after Tax (NOPAT)		 10 11 11 18 7.91 7.37 6.73 9.15 16 15 -11
Normalized NOPAT Margin		 12.76% 12.49% 12.42% 20.41% 9.41% 7.93% 7.63% 9.28% 14.30% 12.44% -19.04%
Pre Tax Income Margin		 11.54% 16.02% 13.47% 26.62% 13.58% 12.11% 9.76% 13.19% 20.09% 18.45% -25.99%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 7.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 6.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 4.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 2.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 16.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

MiMedx Group (NASDAQ: MDXG) shows a clear improvement in profitability and cash generation over the last year, with a much stronger balance sheet than in 2023. Revenue has continued to grow, operating margins have improved, and the company ended 2025 with a sizable cash position. That said, the business still carries notable liabilities, and quarterly profitability can be lumpy because of expense swings and non-operating items.

  • Revenue is trending higher. Q4 2025 revenue rose to $118.1 million from $113.7 million in Q3 2025 and $88.2 million in Q1 2025. Full-year momentum looks better than the 2024 comparison periods.
  • Operating income remains solid. Q4 2025 operating income was $21.1 million, up slightly from $22.2 million in Q3 but far better than the much weaker quarters seen back in early 2023.
  • Cash flow is strong. The company generated $25.0 million in operating cash flow in Q4 2025, after $29.3 million in Q3 and $14.4 million in Q2. That is a healthy sign for a medical products company.
  • Cash and equivalents increased meaningfully. Cash rose to $142.1 million at the end of Q3 2025 from $106.4 million at the start of the year, giving MiMedx more flexibility.
  • Equity improved sharply versus 2023. Total common equity was $238.9 million in Q3 2025, up from just $1.3 million in Q3 2023, reflecting much healthier retained earnings and balance sheet repair.
  • Gross profit dollars are expanding. Q4 2025 gross profit was $99.0 million on $118.1 million of revenue, showing the company continues to convert sales into strong gross profit.
  • Per-share earnings improved year over year. Q3 2025 diluted EPS was $0.11 versus $0.05 in Q1 2025 and negative earnings in earlier 2023 periods.
  • Debt levels are manageable but still present. As of Q3 2025, MiMedx had $1.4 million of short-term debt and $16.8 million of long-term debt, which is not excessive relative to its cash balance, but still worth monitoring.
  • Working capital remains solid. Current assets of $254.1 million versus current liabilities of $57.7 million in Q3 2025 suggest a comfortable liquidity position.
  • Operating expenses remain high. SG&A was $73.1 million in Q4 2025, still a very large cost base relative to revenue and a key factor investors should watch.
  • Quarterly results can be volatile. Net income and EPS have swung materially over the past several years, especially when comparing 2023 to 2025, which suggests some instability in the bottom line.
  • The company still carries notable liabilities. Total liabilities were $80.0 million in Q3 2025, so while the balance sheet is improved, it is not debt-free and remains sensitive to execution.

Overall, MDXG looks materially stronger than it did two years ago. Revenue growth, consistent operating cash flow, and a much larger cash cushion are all positives. The main questions for investors are whether the company can keep scaling revenue while controlling SG&A and whether recent profitability can be sustained quarter after quarter.

07/25/26 08:06 AM ETAI Generated. May Contain Errors.

MiMedx Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, MiMedx Group's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

MiMedx Group's net income appears to be on an upward trend, with a most recent value of $48.58 million in 2025, rising from $29.45 million in 2015. The previous period was $42.42 million in 2024. Check out MiMedx Group's forecast to explore projected trends and price targets.

MiMedx Group's total operating income in 2025 was $63.89 million, based on the following breakdown:
  • Total Gross Profit: $345.62 million
  • Total Operating Expenses: $281.73 million

Over the last 10 years, MiMedx Group's total revenue changed from $187.30 million in 2015 to $418.63 million in 2025, a change of 123.5%.

MiMedx Group's total liabilities were at $86.11 million at the end of 2025, a 21.6% increase from 2024, and a 208.3% increase since 2015.

In the past 10 years, MiMedx Group's cash and equivalents has ranged from $27.48 million in 2017 to $166.12 million in 2025, and is currently $166.12 million as of their latest financial filing in 2025.

Over the last 10 years, MiMedx Group's book value per share changed from 0.99 in 2015 to 1.73 in 2025, a change of 74.8%.


Related Companies

Financial statements for NASDAQ:MDXG last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel